The West Midlands epithelial ovarian cancer adjuvant therapy trial.
In a multicentre prospective randomized controlled trial, single agent cisplatinum was compared with whole abdomino-pelvic moving strip radiotherapy in the management of Stage IC-III epithelial ovarian cancer patients who had no macroscopic residual disease after primary surgery. Over a 6-year period 40 eligible patients were recruited, 15 of whom had Stage III disease. The overall 5-year survival was 60% with no significant survival difference between the treatment groups. Acute toxicity was common in both arms and six (11%) patients experienced significant long term disability.
Redman
C W
CW
West Midlands CRC Clinical Trials Unit, Queen Elizabeth Medical Centre, Birmingham, UK.
Mould
J
J
Warwick
J
J
Rollason
T
T
Luesley
D M
DM
Budden
J
J
Lawton
F G
FG
Blackledge
G R
GR
Chan
K K
KK
D017024:Chemotherapy, Adjuvant; D002945:Cisplatin / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008875:Middle Aged; D010051:Ovarian Neoplasms / Q000401:mortality / Q000628:therapy*; D011182:Postoperative Care; D011446:Prospective Studies; D011878:Radiotherapy / Q000009:adverse effects / Q000379:methods; D012086:Reoperation; D015996:Survival Rate; D013997:Time Factors
D002945:Cisplatin